#1 no pasa nada. Recuerda que la mortalidad de la vacuna hará que nadie desarrolle la enfermedad porque morirá antes
Edit: enfermedad que, por cierto: Se desconoce la causa de la esclerosis múltiple. Se considera una enfermedad de origen inmunitaria en la cual el sistema inmunitario del cuerpo ataca a sus propios tejidos. En el caso de la esclerosis múltiple, este mal funcionamiento del sistema inmunitario destruye la sustancia grasa que recubre y protege las fibras nerviosas del cerebro y la médula espinal (mielina).
Si de verdad descubrieron la causa, lo mismo les dan el Nobel
#4 Cada vez tengo más claro a qué se debe el empeño de esta gentuza en difundir su propaganda, amigo. Ese grupo no es nada si no consiguen más adeptos, y quieren ser un grupo con notoriedad. Pasa lo mismo con el grupo de homeópatas, o muy parecido.
#5 ¿Estás llamando gentuza a la Organización Mundial de la Salud, que es quien ha publicado ese estudio en su propia web? ¿Qué te está pasando? ¿No te habrá abducido algún alienígena?
Luego, al intentar verlo, no puedes, o no sé cómo hacerlo. Pero clicando en uno de los enlaces parece que llegas a la revista sobre esclerosis múltiple donde este artículo se publicó, el Multiple Sclerosis Journal: journals.sagepub.com/doi/epub/10.1177/13524585221123682
En ese documento, finalmente, se encuentra el artículo. Lo pego en su totalidad:
EP0942
Covid-19 vaccination can induce multiple sclerosis via cross-reactive CD4+ T cells recognizing SARS-CoV-2 spike protein and myelin peptides
Y. Qiu1, M. Batruch2, R. Naghavian2, I. Jelcic2, B. Vlad1, M. Hilty1, B. Ineichen3, J. Wang1, M. Sospedra1, R. Martin1
1University Hospital Zürich, Neurology, Zürich, Switzerland, 2University Hospital Zürich, Zürich, Switzerland, 3University Hospital Zürich, Neuroradiology, Zürich, Switzerland
Introduction: Infection with the SARS-CoV-2 coronavirus can lead to a wide range of acute and also chronic disease manifestations. The rapidly developed vaccinations are highly effective in preventing severe disease courses and have been proven safe. Both natural infection and, to a much lower extent, the mRNA-based vaccinations can be accompanied by transient autoimmune phenomena or onset of autoimmune diseases.
Objectives: We report here two cases of multiple sclerosis (MS) with clinical and new radiological signs beginning in close temporal relation to spike (S) protein mRNA-based vaccinations.
Aims: To establish that the onset of MS in these two cases is very likely caused by CD4+ T cell clones that cross-recognize SARS-CoV-2 S protein-derived peptides and peptides derived from myelin proteins, which have previously been implicated in MS.
Methods: Spike specific CD4+ T cells from peripheral blood and CD4+ T cells from CSF sample were isolated and expanded for autoantigen screening test. A list of well-known MS-related autoantigens including immunodominant peptides and isoforms from MBP, MOG, PLP, RASGRP2, TSTA3 peptides were included to assess T cell reactivity. CD4+ CFSElow fraction were sorted after stimulate with positive autoantigen pools or SARS-Cov-2 Spike protein, followed by expansion and testing with autoantigen peptides and Spike protein. Supernatant from cell culture were further analyzed for IFN-gamma secretion.
Results: Self-reactive T cells were detected from Spike specific T cell population in both patients. CD4+ T from CSF also showed reactivity to MBP, MOG, PLP peptide pools. Finally, we found proinflammatory T cell clones that recognize both Spike protein and immunodominant MBP peptides and MOG peptides, which have previously been implicated in MS.
Conclusions: Detailed studies of both peripheral blood- and CSF-derived CD4+ T cells show that the onset of MS in these two cases is very likely caused by CD4+ T cell clones that cross-recognize SARS-CoV-2 S protein-derived peptides and peptides derived from myelin proteins, which have previously been implicated in MS.
Disclosure
Unrestricted grants from Biogen, Novartis, Roche, Third Rock; advisory roles and lectures for Roche, Novartis, Biogen, Genzyme, Neuway, CellProtect, Third Rock; patent holder and co-holder on patents of: daclizumab in MS, JCV VP1 for vaccination against PML; JCV-specific neutralizing antibodies to treat PML; antigen-specific tolerization with peptide-coupled cells and novel autoantigens in MS; co-founder of Abata, co-founder and co-owner of Cellerys
*
Edit: enfermedad que, por cierto:
Se desconoce la causa de la esclerosis múltiple. Se considera una enfermedad de origen inmunitaria en la cual el sistema inmunitario del cuerpo ataca a sus propios tejidos. En el caso de la esclerosis múltiple, este mal funcionamiento del sistema inmunitario destruye la sustancia grasa que recubre y protege las fibras nerviosas del cerebro y la médula espinal (mielina).
Si de verdad descubrieron la causa, lo mismo les dan el Nobel
*
Para poder ver lo que pone, y no lo que dice este que pone.
Luego, al intentar verlo, no puedes, o no sé cómo hacerlo.
En ese documento, finalmente, se encuentra el artículo. Lo pego en su totalidad:
EP0942
Covid-19 vaccination can induce multiple sclerosis via cross-reactive CD4+ T cells recognizing SARS-CoV-2 spike protein and myelin peptides
Y. Qiu1, M. Batruch2, R. Naghavian2, I. Jelcic2, B. Vlad1, M. Hilty1, B. Ineichen3, J. Wang1, M. Sospedra1, R. Martin1
1University Hospital Zürich, Neurology, Zürich, Switzerland, 2University Hospital Zürich, Zürich, Switzerland, 3University Hospital Zürich, Neuroradiology, Zürich, Switzerland
Introduction: Infection with the SARS-CoV-2 coronavirus can lead to a wide range of acute and also chronic disease manifestations. The rapidly developed vaccinations are highly effective in preventing severe disease courses and have been proven safe. Both natural infection and, to a much lower extent, the mRNA-based vaccinations can be accompanied by transient autoimmune phenomena or onset of autoimmune diseases.
Objectives: We report here two cases of multiple sclerosis (MS) with clinical and new radiological signs beginning in close temporal relation to spike (S) protein mRNA-based vaccinations.
Aims: To establish that the onset of MS in these two cases is very likely caused by CD4+ T cell clones that cross-recognize SARS-CoV-2 S protein-derived peptides and peptides derived from myelin proteins, which have previously been implicated in MS.
Methods: Spike specific CD4+ T cells from peripheral blood and CD4+ T cells from CSF sample were isolated and expanded for autoantigen screening test. A list of well-known MS-related autoantigens including immunodominant peptides and isoforms from MBP, MOG, PLP, RASGRP2, TSTA3 peptides were included to assess T cell reactivity. CD4+ CFSElow fraction were sorted after stimulate with positive autoantigen pools or SARS-Cov-2 Spike protein, followed by expansion and testing with autoantigen peptides and Spike protein. Supernatant from cell culture were further analyzed for IFN-gamma secretion.
Results: Self-reactive T cells were detected from Spike specific T cell population in both patients. CD4+ T from CSF also showed reactivity to MBP, MOG, PLP peptide pools. Finally, we found proinflammatory T cell clones that recognize both Spike protein and immunodominant MBP peptides and MOG peptides, which have previously been implicated in MS.
Conclusions: Detailed studies of both peripheral blood- and CSF-derived CD4+ T cells show that the onset of MS in these two cases is very likely caused by CD4+ T cell clones that cross-recognize SARS-CoV-2 S protein-derived peptides and peptides derived from myelin proteins, which have previously been implicated in MS.
Disclosure
Unrestricted grants from Biogen, Novartis, Roche, Third Rock; advisory roles and lectures for Roche, Novartis, Biogen, Genzyme, Neuway, CellProtect, Third Rock; patent holder and co-holder on patents of: daclizumab in MS, JCV VP1 for vaccination against PML; JCV-specific neutralizing antibodies to treat PML; antigen-specific tolerization with peptide-coupled cells and novel autoantigens in MS; co-founder of Abata, co-founder and co-owner of Cellerys
*